Trials / Unknown
UnknownNCT04348149
Lindera Obtusiloba for Non-small Cell Lung Cancer
Adjunctive Administration of Lindera Obtusiloba on Non-small Cell Lung Cancer Patients Who Receive PD-1 Inhibitors: a Randomized Exploratory Pilot Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Jun-Yong Choi · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1 inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Lindera obtusiloba extract | One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks. |
Timeline
- Start date
- 2018-12-28
- Primary completion
- 2020-12-27
- Completion
- 2020-12-27
- First posted
- 2020-04-16
- Last updated
- 2020-04-16
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04348149. Inclusion in this directory is not an endorsement.